Drug search by name

Signifor (Pasireotide Extended-Release Injection) and QT prolongation

Result of checking the interaction of drug Signifor (Pasireotide Extended-Release Injection) and disease QT prolongation for safety when used together.

Check result:

Signifor (Pasireotide Extended-Release Injection) <> QT prolongation

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of pasireotide is associated with QT prolongation. Pasireotide should be used with caution in patients who are at significant risk of developing QT prolongation. It is recommended to correct levels of hypokalemia and hypomagnesemia prior to starting therapy with this agent. Assess ECG at the beginning of therapy and monitor during therapy. Care should be taken in predisposed patients.

Signifor (Pasireotide Extended-Release Injection)

Generic Name: pasireotide

Brand Name: Signifor, Signifor LAR

Synonyms: Signifor, Signifor Injection

What is Signifor (Pasireotide Extended-Release Injection)?